Avaliação clínica do biovidro 45s5 no tratamento da hipersensibilidade dentinária: ensaio clínico randomizado

Abstract

Dentin hypersensitivity (DH) is an exaggerated response of exposed dentin to a non-harmful sensory stimulus, characterized by acute, short-lasting pain. It affects 11% to 33% of patients and represents a clinical challenge. Although various therapies are used, there is no consensus on the ideal treatment. This study aims to evaluate the efficacy of bioglass in controlling dentin hypersensitivity (DH), considering its prevalence and impact on quality of life. This randomized, blinded, split-mouth clinical trial involved 24 volunteers. A total of 66 teeth were evaluated and distributed into two groups according to the treatment applied: Group OXABF (Oxagel BF) and Group B45S5 (Bioglass 45S5 gel (10%). Clinical efficacy was assessed immediately and after three months by two blinded and calibrated evaluators. The variables were dentin sensitivity, measured using the Visual Analog Scale (VAS) after tactile and evaporative stimuli, and oral health-related quality of life, assessed using the Dentine Hypersensitivity Experience Questionnaire (DHEQ-15). For the statistical analysis of the nonparametric sensitivity data, the Mann-Whitney test was used for comparisons between independent groups, and the Friedman test, followed by the Durbin-Conover post-test, was used to analyze differences over time in paired samples. In the DHEQ-15 analysis, comparisons between assessment time points were performed using the Wilcoxon test for paired samples. Regarding the results, no significant differences were observed between the groups in the same period and under the same stimulus (p>0.05). However, in the immediate period, both treatments were effective in reducing sensitivity, regardless of the type of stimulus applied (p<0.05), and this improvement was maintained after three months of follow-up. The application of the DHEQ-15 instrument demonstrated a significant improvement in quality of life related to dentin hypersensitivity after three months of follow-up, with a significant reduction in the total score (p<0.05) and statistical differences in 13 of the 15 questions evaluated. It was concluded that both Biovidro 45S5 and Oxagel BF were effective in reducing immediate dentin sensitivity, with maintenance of the effects over three months, demonstrating their clinical efficacy in managing hypersensitivity and improving quality of life.